Lebanon Pharmaceuticals & Healthcare Q4 2006

Published by: Business Monitor International

Published: Oct. 1, 2006 - 66 Pages

Table of Contents

Chapter 1 - Executive Summary

Lebanon Pharmaceuticals & Healthcare Industry SWOT

Chapter 2 - Lebanon: Business Environment Ranking

Business Environment Ranking: Middle East & Africa

Chapter 3 - Market Summary

Chapter 4 - Regulatory Regime

Intellectual Property Developments

Table: Losses Due to Counterfeit Drugs in the MENA Region, 2004

Pricing & Reimbursement Issues

Table: Lebanon Incremental Drug Margins

Chapter 5 - Industry Developments

Healthcare Sector

Pharmaceuticals Sector

Regional Developments

Chapter 6 - Industry Forecast Scenario

Key Growth Factors - Industry

Lebanon: Prescription % OTC Market Forecasts

Table: Lebanon Drug-Market Forecasts

Key Growth Factors - Macroeconomic

Table: Economic Activity

Prescription Market Forecast

Table: Lebanon Prescription Market Forecast

OTC Market Forecast

Table: Lebanon OTC Market Forecast

Generics & Branded Market Forecasts

Table: Genenrics: Market Share (2005)

Table: Lebanon Generics Market Forecast

Export/Import Market Forecasts

Table: Lebanon Export/Import Forecasts

Other Healthcare Data Forecasts

Table: Lebanon Other Healthcare Forecast

Chapter 7 - Country Snapshot: Lebanon Demographic Data

Section 1: Population:

Table: Demographic Indicators (2005)

Table: Rural/Urban Breakdown

Section 2: Education & Healthcare

Table: Education

Table: Healthcare: Vital Statistics

Table: Healthcare: Expenditure

Chapter 8 - Competitive Landscape

Company Profiles

Lebanon Pharmaceuticals & Healthcare Report Q3 2006

Novartis

Merck & Co

Johnson & Johnson

Sanofi-Aventis

Abbott Laboratories

Chapter 9 - BMI Forecast Modelling

How We Generate Our Industry Forecasts

Pharmaceutical Industry

Chapter 10 - Appendix: Regional Demographic Data

The Long View: Data Over The Economic Cycle (2000-2007)

Population

Household Spending Per Capita, US$

Private Consumption Per Capita, US$ PPP

Market Size, GDP, US$bn

Abstract

The Lebanese pharmaceutical market has shown solid growth in recent years, with annual expansion of 6-7%, although this positive trend has been interrupted by the recent conflict. Particularly damaging has been the Israeli blockade, considering that Lebanon is reliant on imports for around 95% of pharmaceutical consumption.

BMI forecasts that the Lebanese drug market will be worth US$612.5mn at retail prices by 2010. Per-capita drug expenditure is expected to reach US$154.4 in 2010. Public-sector health expenditure is expected to remain almost unchanged at 30% of the total expenditure in healthcare. Drug prices in the country remain relatively high by regional standards. However, the government is said to be considering implementing a new pricing system, which would be based on the reference prices of drugs in similar markets around the world. This is unlikely to encourage multinational sector investment, but will enhance public access to medicines. Only about 62% of Lebanese have health insurance - either public or private - to help cover their drug costs.

Prescription drugs dominate the market, with OTC drugs accounting for approximately 10% of the market. Generic drugs take only a small market share due to a lack of awareness of their merits among both consumers and health professionals.

BMI's adjusted Business Environment Rankings for the Middle East reveal that Lebanon is in 11th place, ahead only of Iran, Nigeria and Zimbabwe. This is primarily due to a number of regulatory barriers such as lax intellectual property (IP) standards. Lebanon's uncertain long term political and economic climate also has a negative impact on our survey.

In the future, Lebanon will have to tighten its intellectual property (IP) regime if it wishes to attract greater foreign direct investment (FDI), and help its local industry to develop. Currently, the IP regime falls short of international standards, particularly in areas such as data exclusivity and pipeline protection. Counterfeiting is also rife, severely impacting sales for multinational companies. As a result, these are more likely to raise prices, in order to recoup losses, or economise in other areas such as R&D.

About MarketResearch.com
MarketResearch.com is an online aggregator selling over 250,000 market research reports, company profiles and country profiles from over 650 research firms. Our reports will provide you with the critical business and competitive intelligence you need for strategic planning and marketing research. Coverage includes the US, UK, Europe, Asia and global markets.